Your browser is no longer supported. Please, upgrade your browser.
Settings
TPTX Turning Point Therapeutics, Inc. daily Stock Chart
TPTX [NASD]
Turning Point Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.77 Insider Own0.10% Shs Outstand35.53M Perf Week0.77%
Market Cap1.90B Forward P/E- EPS next Y-3.22 Insider Trans-76.93% Shs Float33.29M Perf Month13.66%
Income- PEG- EPS next Q-0.64 Inst Own73.40% Short Float6.76% Perf Quarter18.77%
Sales- P/S- EPS this Y-49.40% Inst Trans28.51% Short Ratio5.99 Perf Half Y46.03%
Book/sh13.01 P/B4.11 EPS next Y6.90% ROA- Target Price61.13 Perf Year-
Cash/sh4.85 P/C11.02 EPS next 5Y- ROE- 52W Range24.21 - 58.56 Perf YTD84.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.31% Beta-
Dividend %- Quick Ratio36.60 Sales past 5Y- Gross Margin- 52W Low119.37% ATR2.65
Employees77 Current Ratio36.60 Sales Q/Q- Oper. Margin- RSI (14)61.23 Volatility5.73% 4.95%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.74 Prev Close53.46
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume376.02K Price53.11
Recom1.40 SMA201.30% SMA5020.30% SMA20028.63% Volume231,567 Change-0.65%
Nov-14-19Initiated ROTH Capital Buy $65
Sep-25-19Initiated H.C. Wainwright Buy $70
Sep-10-19Initiated Wedbush Outperform
Jul-24-19Initiated Guggenheim Buy $58
May-13-19Initiated Wells Fargo Outperform
May-13-19Initiated SVB Leerink Outperform $42
May-13-19Initiated RBC Capital Mkts Outperform $48
May-13-19Initiated Goldman Buy $50
Dec-10-19 08:33AM  Turning Point (TPTX) Catches Eye: Stock Jumps 6.1% Zacks
Nov-19-19 07:24AM  Weighing the Risk-Reward in Turning Point Therapeutics TheStreet.com
Nov-13-19 08:30AM  Turning Point Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-12-19 08:30AM  Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients GlobeNewswire
Nov-11-19 08:30AM  Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Nov-08-19 10:34AM  The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme Zacks
Nov-07-19 08:18AM  4 Best-Performing IPOs So Far in 2019 Zacks
Nov-04-19 04:05PM  Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results GlobeNewswire
Oct-28-19 08:03PM  Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX) Insider Monkey
Oct-21-19 06:00AM  Turning Point Therapeutics to Host Third Quarter 2019 Conference Call GlobeNewswire
Sep-30-19 08:30AM  Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Sep-18-19 10:15AM  Is Failure in Store for the WeWork IPO? InvestorPlace -6.25%
Sep-11-19 07:15PM  Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $450,000 ... GuruFocus.com
Sep-09-19 01:57PM  Short Squeeze Candidates: 10 Most Heavily Shorted Stocks Benzinga
Sep-05-19 08:34PM  Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-03-19 04:14PM  Turning Point Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -6.46%
04:01PM  Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Aug-29-19 09:16PM  3 New Biotech Stocks That Keep On Soaring Motley Fool
Aug-28-19 09:00AM  Turning Point Therapeutics Participate in Upcoming Investor Conferences GlobeNewswire +5.63%
Aug-06-19 04:05PM  Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results GlobeNewswire
Aug-01-19 02:31PM  What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register? Simply Wall St.
Jul-31-19 04:30PM  Turning Point Therapeutics CEO to Present at Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
08:30AM  Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors GlobeNewswire
Jul-29-19 08:30AM  Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer GlobeNewswire
Jul-25-19 08:30AM  Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors GlobeNewswire
Jul-22-19 09:00AM  Turning Point Therapeutics to Host Second Quarter 2019 Conference Call GlobeNewswire
Jun-20-19 09:00AM  Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study GlobeNewswire
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-04-19 08:30AM  Turning Point Therapeutics CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
May-31-19 08:30AM  Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer GlobeNewswire -10.26%
May-24-19 09:36AM  Bay Area figures prominently in hottest IPOs so far this year American City Business Journals
May-15-19 09:00AM  Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor GlobeNewswire
May-14-19 04:30PM  Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference GlobeNewswire
09:00AM  Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors GlobeNewswire
May-06-19 09:00AM  Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study GlobeNewswire
Apr-29-19 12:57PM  Weekly CEO Buys Highlight GuruFocus.com +5.69%
Apr-24-19 08:15PM  Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $216,000 ... GuruFocus.com
Apr-22-19 04:05PM  Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-17-19 11:01AM  Turning Point Therapeutics IPO: What You Need To Know Benzinga
Apr-16-19 10:57PM  Turning Point Therapeutics Announces Pricing of Initial Public Offering Business Wire
Apr-14-19 09:53AM  IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance Benzinga
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naive and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cui Jingrong JeanChief Scientific OfficerDec 09Sale55.3211,500636,2291,060,719Dec 09 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 06Sale50.7750,8902,583,5881,072,219Dec 09 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 05Sale51.9556,1102,914,9361,123,109Dec 09 08:44 PM